Minucci Rita, De Silvestri Annalisa, Cambieri Patrizia, Corbella Marta, Pellegrini Carlo, Roda Silvia, Dezza Chiara, Pelenghi Stefano, Bruno Raffaele, Belliato Mirko, Seminari Elena
Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
SSD Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Transpl Infect Dis. 2025 Apr 20;27(3):e70031. doi: 10.1111/tid.70031.
Infections occurring in the early post-heart transplant (HT) period heavily contribute to morbidity and mortality. Our goal is to evaluate the incidence of hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAPs) and/or bloodstream infections (BSIs) after HT during the intensive care unit (ICU) stay and identify their associated risk factors in our tertiary hospital.
Observational prospective study including all adult patients who consecutively underwent HT from January 1, 2015 to August 31, 2023 at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. HAP/VAPs and BSIs diagnosed during ICU were included in the analysis.
A total of 106 patients were included, 38 of whom had at least one infectious episode (35.8%), for a total of 57 independent episodes and their incidence was 2.2 per 100 days (95% CI 1.7-2.8). Length of ICU stay was 8 days (IQR: 6-11) for patients without infectious events and 27 days (IQR 14-52) for those with infectious events (p < 0.001). Gram-negative bacteria were associated with 62.8% of BSIs (mainly Enterobacterales) and with 77.9% of HAP/VAP, in this setting Pseudomonas aeruginosa accounted for 17.6% of infections while Klebsiella spp. accounted for 22.1% of infections. Colonization with resistant bacteria (HR 2.21, 95% CI 1.12-4.35) was associated with increased risk of infections while perioperative antimicrobial prophylaxis (PAP) covering Gram-negative bacteria at transplant (HR 0.45, 95% CI 0.23-0.90, p = 0.023) was a protective factor.
This study shows that Gram-negative infections represent the major challenge for HT patients during ICU stay and shows some evidence in support of the PAP covering Gram-negative infections at transplant.
心脏移植(HT)术后早期发生的感染对发病率和死亡率有很大影响。我们的目标是评估重症监护病房(ICU)住院期间HT后医院获得性肺炎/呼吸机相关性肺炎(HAP/VAP)和/或血流感染(BSI)的发生率,并确定我们三级医院中其相关危险因素。
前瞻性观察性研究,纳入2015年1月1日至2023年8月31日在意大利帕维亚圣马泰奥综合医院基金会连续接受HT的所有成年患者。分析ICU期间诊断出的HAP/VAP和BSI。
共纳入106例患者,其中38例至少有一次感染发作(35.8%),共有57次独立发作,其发生率为每100天2.2次(95%CI 1.7-2.8)。无感染事件的患者ICU住院时间为8天(IQR:6-11),有感染事件的患者为27天(IQR 14-52)(p<0.001)。在这种情况下,革兰氏阴性菌与62.8%的BSI(主要是肠杆菌科)和77.9%的HAP/VAP相关,铜绿假单胞菌占感染的17.6%,克雷伯菌属占感染的22.1%。耐药菌定植(HR 2.21,95%CI 1.12-4.35)与感染风险增加相关,而移植时覆盖革兰氏阴性菌的围手术期抗菌预防(PAP)(HR 0.45,95%CI 0.23-0.90,p=0.023)是一个保护因素。
本研究表明,革兰氏阴性菌感染是HT患者在ICU住院期间的主要挑战,并显示出一些证据支持移植时覆盖革兰氏阴性菌感染的PAP。